Double trouble: IRAK1/4 inhibitors in AML/MDS


In this latest commentary, we focus on research published in blood by Bennete et al. ,which explores the therapeutic role of IRAK1/4. Interleukin-1 receptor kinases are mediators for signaling pathways and specifically IRAK 4 is currently under investigation as therapeutic target. The researchers show in their publication that to succeed targeting leukemic stem/progenitor cells IRAK1 and IRAK4 need to be cotargeted. Find out about the detailed reasoning in our commentary linked below:

Hannah J. Uckelmann, Jan-Henning Klusmann; Double trouble: IRAK1/4 inhibitors in AML/MDS. Blood 2023; 142 (11): 945–946. doi:

Back to blog overview

Other Blogposts